article thumbnail

First To Know Syphilis Test Offers At-Home Diagnosis in 15 Minutes

XTalks

The test, the first of its kind approved for over-the-counter (OTC) use in the US, detects antibodies for Treponema pallidum , the bacterium responsible for syphilis. NOWDiagnostics’ First To Know Syphilis Test circumvents these barriers with a convenient, in-home solution offering results in just 15 minutes. percent for positive cases.

Bacterium 104
article thumbnail

Intravacc gets NIAID contract for intranasal gonorrhoea vaccine development

Pharmaceutical Technology

The company will create a comprehensive manufacturing process for NGoXIM to generate batches of the vaccine that are Good Manufacturing Practices-compliant. Therapyx will develop and manufacture the IL-12-containing microspheres in the vaccine called GneX12.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Common bacteria modified to make designer sugar-based drug

Scienmag

Process paves a road to safe, ethical, and fast drug manufacturing Credit: Rensselaer Polytechnic Institute TROY, N.Y. — Envisioning an animal-free drug supply, scientists have — for the first time — reprogrammed a common bacterium to make a designer polysaccharide molecule used in pharmaceuticals and nutraceuticals.

article thumbnail

Lumen Bioscience’s LMN-201 secures FDA fast track status to treat CDI

Pharmaceutical Technology

An investigational orally delivered biologic drug, LMN-201 is a cocktail of four therapeutic proteins that act synergistically to neutralise the C difficile bacterium and the toxin. It is compatible with standard-of-care antibiotics.

Bacterium 130
article thumbnail

A new era in diagnostics: The growing demand for POC testing

Pharmaceutical Technology

While a significant proportion of this increase is due to the volume of lateral flow tests (LFTs) manufactured to perform mass screening of populations for Covid-19 over the last two years, this trend towards POC diagnostics is positive news. Manufacturing challenges. Customisable solutions.

article thumbnail

Non-vaccine nasal spray could protect against COVID-19

pharmaphorum

The spray is based on the SporeVax technology developed at Sporegen by Royal Holloway University Professor Simon Cutting and takes the form of heat killed spores of a bacterium – Bacillus subtilis – that stimulate a part of the innate immune system known as mucosal immunity. Image: Allonweiner at English Wikipedia.

article thumbnail

As gonorrhoea threat grows, Intravacc gets $14m for vaccine hunt

pharmaphorum

Some gonorrhoea infections have become untreatable with all seven main antibiotic classes – a situation last encountered in the 1920s before the advent of effective drugs for the bacterium. At the moment most cases are treated with azithromycin, with intravenous ceftriaxone generally reserved as a last-line therapy.